{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:58:38Z","timestamp":1778860718304,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shanghai Municipal Science and Technology Program","award":["14431904100"],"award-info":[{"award-number":["14431904100"]}]},{"name":"National S and T major projects of China (Key Innovative Drug Development)","award":["2014ZX09101043"],"award-info":[{"award-number":["2014ZX09101043"]}]},{"name":"Shanghai Industry-Academia-Research Collaboration Program","award":["CXY-2013-54"],"award-info":[{"award-number":["CXY-2013-54"]}]},{"DOI":"10.13039\/501100013286","name":"Specialized Research Fund for the Doctoral Program of Higher Education of China","doi-asserted-by":"crossref","award":["20130073120110"],"award-info":[{"award-number":["20130073120110"]}],"id":[{"id":"10.13039\/501100013286","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medicine Science\/Engineering Hybrid Project of Shanghai Jiao Tong University","award":["YG2013MS09"],"award-info":[{"award-number":["YG2013MS09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00262-016-1928-0","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T12:11:46Z","timestamp":1479730306000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models"],"prefix":"10.1007","volume":"66","author":[{"given":"Aizhang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhibing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"1928_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/Nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967\u2013974. doi: 10.1038\/Nature04483","journal-title":"Nature"},{"key":"1928_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00262-006-0234-7","volume":"56","author":"K Mimura","year":"2007","unstructured":"Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H (2007) Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 56:761\u2013770. doi: 10.1007\/s00262-006-0234-7","journal-title":"Cancer Immunol Immunother"},{"key":"1928_CR3","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:4878\u20134886. doi: 10.1182\/blood-2002-07-1956","journal-title":"Blood"},{"key":"1928_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539\u2013549. doi: 10.1158\/0008-5472.CAN-12-2325","journal-title":"Cancer Res"},{"key":"1928_CR5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00262-008-0524-3","volume":"57","author":"AW Griffioen","year":"2008","unstructured":"Griffioen AW (2008) Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol Immunother 57:1553\u20131558. doi: 10.1007\/s00262-008-0524-3","journal-title":"Cancer Immunol Immunother"},{"key":"1928_CR6","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676. doi: 10.1056\/NEJMoa072113","journal-title":"N Engl J Med"},{"key":"1928_CR7","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550. doi: 10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"key":"1928_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342. doi: 10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"key":"1928_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","volume":"8","author":"JM Ebos","year":"2011","unstructured":"Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8:210\u2013221. doi: 10.1038\/nrclinonc.2011.21","journal-title":"Nat Rev Clin Oncol"},{"key":"1928_CR10","doi-asserted-by":"crossref","first-page":"11545","DOI":"10.1073\/pnas.191112198","volume":"98","author":"YQ Wei","year":"2001","unstructured":"Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ, Liu F, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F, Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ, Li Q, Wu Y, Ding ZY, Hu B, Hu M, Zhang W (2001) Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 98:11545\u201311550","journal-title":"Proc Natl Acad Sci USA"},{"key":"1928_CR11","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/srep03380","volume":"3","author":"M Kyutoku","year":"2013","unstructured":"Kyutoku M, Nakagami H, Koriyama H, Tomioka H, Nakagami F, Shimamura M, Kurinami H, Zhengda P, Jo DH, Kim JH, Takakura N, Morishita R (2013) Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep 3:3380. doi: 10.1038\/srep03380","journal-title":"Sci Rep"},{"key":"1928_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10456-006-9062-9","volume":"10","author":"M Bequet-Romero","year":"2007","unstructured":"Bequet-Romero M, Ayala M, Acevedo BE, Rodriguez EG, Ocejo OL, Torrens I, Gavilondo JV (2007) Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl\/6 mice. Angiogenesis 10:23\u201334. doi: 10.1007\/s10456-006-9062-9","journal-title":"Angiogenesis"},{"key":"1928_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ygyno.2010.07.037","volume":"119","author":"B Wang","year":"2010","unstructured":"Wang B, Kaumaya PTP, Cohn DE (2010) Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol 119:564\u2013570. doi: 10.1016\/j.ygyno.2010.07.037","journal-title":"Gynecol Oncol"},{"key":"1928_CR14","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1073\/pnas.0611022104","volume":"104","author":"FH Rad","year":"2007","unstructured":"Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D, Uzan G (2007) VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 104:2837\u20132842. doi: 10.1073\/pnas.0611022104","journal-title":"Proc Natl Acad Sci USA"},{"key":"1928_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10456-008-9121-5","volume":"11","author":"Y Morera","year":"2008","unstructured":"Morera Y, Bequet-Romero M, Ayala M, Lamdan H, Agger EM, Andersen P, Gavilondo JV (2008) Anti-tumoral effect of active immunotherapy in C57BL\/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 11:381\u2013393. doi: 10.1007\/s10456-008-9121-5","journal-title":"Angiogenesis"},{"key":"1928_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00262-007-0282-7","volume":"56","author":"D Kamstock","year":"2007","unstructured":"Kamstock D, Elmslie R, Thamm D, Dow S (2007) Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 56:1299\u20131309. doi: 10.1007\/s00262-007-0282-7","journal-title":"Cancer Immunol Immunother"},{"key":"1928_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Schluns KS, Davis RE, Hwu P, Overwijk WW (2013) Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 19:465\u2013472. doi: 10.1038\/nm.3105","journal-title":"Nat Med"},{"key":"1928_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00262-013-1435-5","volume":"62","author":"EP Salerno","year":"2013","unstructured":"Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund\u2019s adjuvant, with or without peptide. Cancer Immunol Immunother 62:1149\u20131159. doi: 10.1007\/s00262-013-1435-5","journal-title":"Cancer Immunol Immunother"},{"key":"1928_CR19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/cimm.2001.1883","volume":"214","author":"Z Chen","year":"2001","unstructured":"Chen Z, Dehm S, Bonham K, Kamencic H, Juurlink B, Zhang X, Gordon JR, Xiang J (2001) DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 214:60\u201371","journal-title":"Cell Immunol"},{"key":"1928_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nrc2505","volume":"8","author":"SJ Harper","year":"2008","unstructured":"Harper SJ, Bates DO (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8:880\u2013887. doi: 10.1038\/nrc2505","journal-title":"Nat Rev Cancer"},{"key":"1928_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E","volume":"26","author":"HW Christinger","year":"1996","unstructured":"Christinger HW, Muller YA, Berleau LT, Keyt BA, Cunningham BC, Ferrara N, de Vos AM (1996) Crystallization of the receptor binding domain of vascular endothelial growth factor. Proteins 26:353\u2013357. doi: 10.1002\/(SICI)1097-0134(199611)26:3<353:AID-PROT9>3.0.CO;2-E","journal-title":"Proteins"},{"key":"1928_CR22","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1074\/jbc.271.13.7788","volume":"271","author":"BA Keyt","year":"1996","unstructured":"Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N (1996) The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788\u20137795","journal-title":"J Biol Chem"},{"key":"1928_CR23","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","volume":"28","author":"HR Shinefield","year":"2010","unstructured":"Shinefield HR (2010) Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine 28:4335\u20134339. doi: 10.1016\/j.vaccine.2010.04.072","journal-title":"Vaccine"},{"key":"1928_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1086\/315324","volume":"181","author":"BM Diethelm-Okita","year":"2000","unstructured":"Diethelm-Okita BM, Okita DK, Banaszak L, Conti-Fine BM (2000) Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. J Infect Dis 181:1001\u20131009. doi: 10.1086\/315324","journal-title":"J Infect Dis"},{"key":"1928_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1134\/s106816201206012x","volume":"38","author":"SI Romaniuk","year":"2012","unstructured":"Romaniuk SI, Kolybo DV, Komisarenko SV (2012) Recombinant diphtheria toxin derivatives: perspectives of application. Russ J Bioorg Chem 38:565\u2013577. doi: 10.1134\/s106816201206012x","journal-title":"Russ J Bioorg Chem"},{"key":"1928_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/357216a0","volume":"357","author":"S Choe","year":"1992","unstructured":"Choe S, Bennett MJ, Fujii G, Curmi PM, Kantardjieff KA, Collier RJ, Eisenberg D (1992) The crystal structure of diphtheria toxin. Nature 357:216\u2013222. doi: 10.1038\/357216a0","journal-title":"Nature"},{"key":"1928_CR27","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1016\/j.vaccine.2007.06.049","volume":"25","author":"B Hansen","year":"2007","unstructured":"Hansen B, Sokolovska A, HogenEsch H, Hem SL (2007) Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 25:6618\u20136624. doi: 10.1016\/j.vaccine.2007.06.049","journal-title":"Vaccine"},{"key":"1928_CR28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2:1097\u20131105. doi: 10.1177\/1947601911423031","journal-title":"Genes Cancer"},{"key":"1928_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11:509\u2013524. doi: 10.1038\/nrclinonc.2014.111","journal-title":"Nat Rev Clin Oncol"},{"key":"1928_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","volume":"27","author":"N McGranahan","year":"2015","unstructured":"McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15\u201326. doi: 10.1016\/j.ccell.2014.12.001","journal-title":"Cancer Cell"},{"key":"1928_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djs033","volume":"104","author":"J Schlom","year":"2012","unstructured":"Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599\u2013613. doi: 10.1093\/jnci\/djs033","journal-title":"J Natl Cancer Inst"},{"key":"1928_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572\u2013576. doi: 10.1038\/nature14001","journal-title":"Nature"},{"key":"1928_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-824X-3-7","volume":"3","author":"A Matejuk","year":"2011","unstructured":"Matejuk A, Leng Q, Chou ST, Mixson AJ (2011) Vaccines targeting the neovasculature of tumors. Vasc Cell 3:7. doi: 10.1186\/2045-824X-3-7","journal-title":"Vasc Cell"},{"key":"1928_CR34","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-06-1105","volume":"12","author":"XY Chen","year":"2006","unstructured":"Chen XY, Zhang W, Wu S, Bi F, Su YJ, Tan XY, Liu JN, Zhang J (2006) Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res 12:5834\u20135840. doi: 10.1158\/1078-0432.CCR-06-1105","journal-title":"Clin Cancer Res"},{"key":"1928_CR35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.2001.19.4.1207","volume":"19","author":"RT Poon","year":"2001","unstructured":"Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207\u20131225","journal-title":"J Clin Oncol"},{"key":"1928_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fimmu.2012.00406","volume":"3","author":"H Hogenesch","year":"2012","unstructured":"Hogenesch H (2012) Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 3:406. doi: 10.3389\/fimmu.2012.00406","journal-title":"Front Immunol"},{"key":"1928_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1086\/317537","volume":"32","author":"B Spellberg","year":"2001","unstructured":"Spellberg B, Edwards JE Jr (2001) Type 1\/Type 2 immunity in infectious diseases. Clin Infect Dis 32:76\u2013102. doi: 10.1086\/317537","journal-title":"Clin Infect Dis"},{"key":"1928_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883\u2013899. doi: 10.1016\/j.cell.2010.01.025","journal-title":"Cell"},{"key":"1928_CR39","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-08-1980","volume":"15","author":"WK Nevala","year":"2009","unstructured":"Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN (2009) Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 15:1931\u20131939. doi: 10.1158\/1078-0432.CCR-08-1980","journal-title":"Clin Cancer Res"},{"key":"1928_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/1471-2407-12-561","volume":"12","author":"S Shimato","year":"2012","unstructured":"Shimato S, Maier LM, Maier R, Bruce JN, Anderson RC, Anderson DE (2012) Profound tumor-specific Th2 bias in patients with malignant glioma. BMC Cancer 12:561. doi: 10.1186\/1471-2407-12-561","journal-title":"BMC Cancer"},{"key":"1928_CR41","doi-asserted-by":"publisher","first-page":"17695","DOI":"10.1038\/srep17695","volume":"5","author":"B Wang","year":"2015","unstructured":"Wang B, Wang X, Wen Y, Fu J, Wang H, Ma Z, Shi Y (2015) Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8(+) T cell response. Sci Rep 5:17695. doi: 10.1038\/srep17695","journal-title":"Sci Rep"},{"key":"1928_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10637-010-9533-0","volume":"30","author":"N Tsavaris","year":"2012","unstructured":"Tsavaris N, Voutsas IF, Kosmas C, Gritzapis AD, Baxevanis CN (2012) Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients. Invest New Drugs 30:395\u2013402. doi: 10.1007\/s10637-010-9533-0","journal-title":"Invest New Drugs"},{"key":"1928_CR43","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72:1070\u20131080. doi: 10.1158\/0008-5472.CAN-11-3218","journal-title":"Cancer Res"},{"key":"1928_CR44","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00262-016-1826-5","volume":"65","author":"F Noble","year":"2016","unstructured":"Noble F, Mellows T, McCormick Matthews LH, Bateman AC, Harris S, Underwood TJ, Byrne JP, Bailey IS, Sharland DM, Kelly JJ, Primrose JN, Sahota SS, Bateman AR, Thomas GJ, Ottensmeier CH (2016) Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother 65:651\u2013662. doi: 10.1007\/s00262-016-1826-5","journal-title":"Cancer Immunol Immunother"},{"key":"1928_CR45","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109:17561\u201317566. doi: 10.1073\/pnas.1215397109","journal-title":"Proc Natl Acad Sci USA"},{"key":"1928_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nm.2306","volume":"17","author":"TL Flach","year":"2011","unstructured":"Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, Prenner E, Ling CC, Tschopp J, Muruve DA, Amrein MW, Shi Y (2011) Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 17:479\u2013487. doi: 10.1038\/nm.2306","journal-title":"Nat Med"},{"key":"1928_CR47","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1021\/bi9009264","volume":"48","author":"A Kyrychenko","year":"2009","unstructured":"Kyrychenko A, Posokhov YO, Rodnin MV, Ladokhin AS (2009) Kinetic intermediate reveals staggered pH-dependent transitions along the membrane insertion pathway of the diphtheria toxin T-domain. Biochemistry 48:7584\u20137594. doi: 10.1021\/bi9009264","journal-title":"Biochemistry"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1928-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1928-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1928-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T09:59:51Z","timestamp":1589709591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1928-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1928-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}